{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:57:33Z","timestamp":1790938653392,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/mp.2009.89","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T08:02:34Z","timestamp":1251792154000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics"],"prefix":"10.1038","volume":"16","author":[{"given":"J L","family":"McClay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D E","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D O","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V I","family":"Vladimirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P F","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E J C G","family":"van den Oord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"BFmp200989_CR1","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha S, Chant D, Welham J, McGrath J . A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.","journal-title":"PLoS Med"},{"key":"BFmp200989_CR2","volume-title":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020","author":"CJL Murray","year":"1996","unstructured":"Murray CJL, Lozpe AD . The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press: Boston, 1996."},{"key":"BFmp200989_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.173.1.11","volume":"173","author":"EC Harris","year":"1998","unstructured":"Harris EC, Barraclough B . Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11\u201353.","journal-title":"Br J Psychiatry"},{"key":"BFmp200989_CR4","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1371\/journal.pmed.0020212","volume":"2","author":"PF Sullivan","year":"2005","unstructured":"Sullivan PF . The genetics of schizophrenia. PLoS Med 2005; 2: e212.","journal-title":"PLoS Med"},{"key":"BFmp200989_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/sj.ejhg.5201571","volume":"14","author":"B Riley","year":"2006","unstructured":"Riley B, Kendler KS . Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006; 14: 669\u2013680.","journal-title":"Eur J Hum Genet"},{"key":"BFmp200989_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.bjp.0707307","volume":"152","author":"D Rognan","year":"2007","unstructured":"Rognan D . Chemogenomic approaches to rational drug design. Br J Pharmacol 2007; 152: 38\u201352.","journal-title":"Br J Pharmacol"},{"key":"BFmp200989_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/35015728","volume":"405","author":"AD Roses","year":"2000","unstructured":"Roses AD . Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857\u2013865.","journal-title":"Nature"},{"key":"BFmp200989_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1176\/appi.ajp.161.5.780","volume":"161","author":"AK Malhotra","year":"2004","unstructured":"Malhotra AK, Murphy GM, Kennedy JL . Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780\u2013796.","journal-title":"Am J Psychiatry"},{"key":"BFmp200989_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0006-3223(99)00059-1","volume":"46","author":"JM Kane","year":"1999","unstructured":"Kane JM . Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46: 1396\u20131408.","journal-title":"Biol Psychiatry"},{"key":"BFmp200989_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1176\/ajp.152.1.153","volume":"152","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY, Okayli G . Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183\u2013190.","journal-title":"Am J Psychiatry"},{"key":"BFmp200989_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/hmg\/11.20.2517","volume":"11","author":"VS Basile","year":"2002","unstructured":"Basile VS, Masellis M, Potkin SG, Kennedy JL . Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517\u20132530.","journal-title":"Hum Mol Genet"},{"key":"BFmp200989_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"MJ Arranz","year":"2007","unstructured":"Arranz MJ, de Leon J . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707\u2013747.","journal-title":"Mol Psychiatry"},{"key":"BFmp200989_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442\u2013473.","journal-title":"Mol Psychiatry"},{"key":"BFmp200989_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1586\/14737159.6.3.277","volume":"6","author":"J de Leon","year":"2006","unstructured":"de Leon J . AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006; 6: 277\u2013286.","journal-title":"Expert Rev Mol Diagn"},{"key":"BFmp200989_CR15","doi-asserted-by":"crossref","unstructured":"Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009.","DOI":"10.1038\/ejhg.2008.264"},{"key":"BFmp200989_CR16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","volume":"308","author":"RJ Klein","year":"2005","unstructured":"Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385\u2013389.","journal-title":"Science"},{"key":"BFmp200989_CR17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1126\/science.1141634","volume":"316","author":"TM Frayling","year":"2007","unstructured":"Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889\u2013894.","journal-title":"Science"},{"key":"BFmp200989_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461\u20131463.","journal-title":"Science"},{"key":"BFmp200989_CR19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1142358","volume":"316","author":"R Saxena","year":"2007","unstructured":"Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331\u20131336.","journal-title":"Science"},{"key":"BFmp200989_CR20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1126\/science.1142382","volume":"316","author":"LJ Scott","year":"2007","unstructured":"Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316: 1341\u20131345.","journal-title":"Science"},{"key":"BFmp200989_CR21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ng2043","volume":"39","author":"V Steinthorsdottir","year":"2007","unstructured":"Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39: 770\u2013775.","journal-title":"Nat Genet"},{"key":"BFmp200989_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"key":"BFmp200989_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","volume":"29","author":"TS Stroup","year":"2003","unstructured":"Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15\u201331.","journal-title":"Schizophr Bull"},{"key":"BFmp200989_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mp.2008.25","volume":"13","author":"PF Sullivan","year":"2008","unstructured":"Sullivan PF, Lin D, Tzeng JY, van den OE, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570\u2013584.","journal-title":"Mol Psychiatry"},{"key":"BFmp200989_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261\u2013276.","journal-title":"Schizophr Bull"},{"key":"BFmp200989_CR26","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Administration Booklet","author":"M First","year":"1994","unstructured":"First M, Spitzer R, Gibbon M, Williams J . Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Administration Booklet. American Psychiatric Press Inc.: Washington, DC, 1994."},{"key":"BFmp200989_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1126\/science.1105436","volume":"307","author":"DA Hinds","year":"2005","unstructured":"Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307: 1072\u20131079.","journal-title":"Science"},{"key":"BFmp200989_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559\u2013575.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1086\/429864","volume":"76","author":"JE Wigginton","year":"2005","unstructured":"Wigginton JE, Cutler DJ, Abecasis GR . A note on exact tests of Hardy\u2013Weinberg equilibrium. Am J Hum Genet 2005; 76: 887\u2013893.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1086\/430507","volume":"76","author":"JK Wittke-Thompson","year":"2005","unstructured":"Wittke-Thompson JK, Pluzhnikov A, Cox NJ . Rational inferences about departures from Hardy\u2013Weinberg equilibrium. Am J Hum Genet 2005; 76: 967\u2013986.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2005.09.002","volume":"82","author":"EJCG Van den Oord","year":"2006","unstructured":"Van den Oord EJCG, Rujescu D, Robles JR, Giegling I, Birrell C, Bukszar J et al. Factor structure and external validity of the PANSS revisited. Schizophr Res 2006; 82: 213\u2013223.","journal-title":"Schizophr Res"},{"key":"BFmp200989_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000285058","volume":"30","author":"L White","year":"1997","unstructured":"White L, Harvey PD, Opler L, Lindenmayer JP, The PANSS Study Group. Psychopathology 1997; 30: 263\u2013274.","journal-title":"Psychopathology"},{"key":"BFmp200989_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.schres.2006.03.021","volume":"85","author":"M van der Gaag","year":"2006","unstructured":"van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 2006; 85: 280\u2013287.","journal-title":"Schizophr Res"},{"key":"BFmp200989_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.schres.2008.09.009","volume":"107","author":"EJCG Van den Oord","year":"2009","unstructured":"Van den Oord EJCG, Adkins DE, McClay J, Lieberman J, Sullivan PF . A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 2009; 107: 13\u201321.","journal-title":"Schizophr Res"},{"key":"BFmp200989_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31\u201341.","journal-title":"Lancet"},{"key":"BFmp200989_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152\u2013163; e-pub 17 November 2008.","journal-title":"Am J Psychiatry"},{"key":"BFmp200989_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.0006-341X.1999.00997.x","volume":"55","author":"B Devlin","year":"1999","unstructured":"Devlin B, Roeder K . Genomic control for association studies. Biometrics 1999; 55: 997\u20131004.","journal-title":"Biometrics"},{"key":"BFmp200989_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1086\/302959","volume":"67","author":"JK Pritchard","year":"2000","unstructured":"Pritchard JK, Stephens M, Rosenberg NA, Donnelly P . Association mapping in structured populations. Am J Hum Genet 2000; 67: 170\u2013181.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904\u2013909.","journal-title":"Nat Genet"},{"key":"BFmp200989_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1086\/516842","volume":"80","author":"MP Epstein","year":"2007","unstructured":"Epstein MP, Allen AS, Satten GA . A simple and improved correction for population stratification in case\u2013control studies. Am J Hum Genet 2007; 80: 921\u2013930.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR41","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1371\/journal.pgen.0020190","volume":"2","author":"N Patterson","year":"2006","unstructured":"Patterson N, Price AL, Reich D . Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.","journal-title":"PLoS Genet"},{"key":"BFmp200989_CR42","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1214\/aos\/1074290335","volume":"31","author":"J Storey","year":"2003","unstructured":"Storey J . The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 2003; 31: 2013\u20132035.","journal-title":"Ann Stat"},{"key":"BFmp200989_CR43","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"J Storey","year":"2003","unstructured":"Storey J, Tibshirani R . Statistical significance for genome-wide studies. Proc Natl Acad Sci USA 2003; 100: 9440\u20139445.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200989_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tig.2003.08.003","volume":"19","author":"EJCG Van den Oord","year":"2003","unstructured":"Van den Oord EJCG, Sullivan PF . False discoveries and models for gene discovery. Trends Genet 2003; 19: 537\u2013542.","journal-title":"Trends Genet"},{"key":"BFmp200989_CR45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289\u2013300.","journal-title":"J R Stat Soc B"},{"key":"BFmp200989_CR46","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/(SICI)1097-0258(19971130)16:22<2511::AID-SIM693>3.0.CO;2-4","volume":"16","author":"BW Brown","year":"1997","unstructured":"Brown BW, Russell K . Methods of correcting for multiple testing: operating characteristics. Stat Med 1997; 16: 2511\u20132528.","journal-title":"Stat Med"},{"key":"BFmp200989_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1534\/genetics.166.1.611","volume":"166","author":"RL Fernando","year":"2004","unstructured":"Fernando RL, Nettleton D, Southey BR, Dekkers JC, Rothschild MF, Soller M . Controlling the proportion of false positives in multiple dependent tests. Genetics 2004; 166: 611\u2013619.","journal-title":"Genetics"},{"key":"BFmp200989_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000076393","volume":"56","author":"EJCG Van den Oord","year":"2003","unstructured":"Van den Oord EJCG, Sullivan PF . A framework for controlling false discovery rates and minimizing the amount of genotyping in the search for disease mutations. Hum Hered 2003; 56: 188\u2013199.","journal-title":"Hum Hered"},{"key":"BFmp200989_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0378-3758(03)00211-8","volume":"124","author":"EL Korn","year":"2004","unstructured":"Korn EL, Troendle J, McShane L, Simon R . Controlling the number of false discoveries: application to high-dimensional genomic data. J Stat Plan Infer 2004; 124: 379\u2013398.","journal-title":"J Stat Plan Infer"},{"key":"BFmp200989_CR50","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.0006-341X.2003.00123.x","volume":"59","author":"CA Tsai","year":"2003","unstructured":"Tsai CA, Hsueh HM, Chen JJ . Estimation of false discovery rates in multiple testing: application to gene microarray data. Biometrics 2003; 59: 1071\u20131081.","journal-title":"Biometrics"},{"key":"BFmp200989_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.mp.4001581","volume":"10","author":"EJCG Van den Oord","year":"2005","unstructured":"Van den Oord EJCG . Controlling false discoveries in candidate gene studies. Mol Psychiatry 2005; 10: 230\u2013231.","journal-title":"Mol Psychiatry"},{"key":"BFmp200989_CR52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/genetics\/164.2.829","volume":"164","author":"C Sabatti","year":"2003","unstructured":"Sabatti C, Service S, Freimer N . False discovery rate in linkage and association genome screens for complex disorders. Genetics 2003; 164: 829\u2013833.","journal-title":"Genetics"},{"key":"BFmp200989_CR53","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/bioinformatics\/btk025","volume":"22","author":"BM Hemminger","year":"2006","unstructured":"Hemminger BM, Saelim B, Sullivan PF . TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics 2006; 22: 626\u2013627.","journal-title":"Bioinformatics"},{"key":"BFmp200989_CR54","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gkj144","volume":"34","author":"AS Hinrichs","year":"2006","unstructured":"Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H et al. The UCSC genome browser database: update 2006. Nucleic Acids Res 2006; 34: D590\u2013D598.","journal-title":"Nucleic Acids Res"},{"key":"BFmp200989_CR55","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nature04226","volume":"437","author":"International HapMap Consortium","year":"2005","unstructured":"International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299\u20131320.","journal-title":"Nature"},{"key":"BFmp200989_CR56","doi-asserted-by":"publisher","first-page":"D173","DOI":"10.1093\/nar\/gkj158","volume":"34","author":"DL Wheeler","year":"2006","unstructured":"Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2006; 34: D173\u2013D180.","journal-title":"Nucleic Acids Res"},{"key":"BFmp200989_CR57","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/genetics\/154.4.1917","volume":"154","author":"D Zaykin","year":"2000","unstructured":"Zaykin D, Young S, Westfall P . Using the false discovery rate in the genetic dissection of complex traits. Genetics 2000; 154: 1917\u20131918.","journal-title":"Genetics"},{"key":"BFmp200989_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.biopsych.2007.04.018","volume":"63","author":"DB Campbell","year":"2008","unstructured":"Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry 2008; 63: 32\u201341.","journal-title":"Biol Psychiatry"},{"key":"BFmp200989_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ajmg.b.30635","volume":"147B","author":"A Meary","year":"2007","unstructured":"Meary A, Brousse G, Jamain S, Schmitt A, Szoke A, Schurhoff F et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2007; 147B: 491\u2013494.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFmp200989_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euroneuro.2007.05.005","volume":"18","author":"N Hamdani","year":"2008","unstructured":"Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, Sarfati Y et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008; 18: 34\u201340.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFmp200989_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-244X-7-22","volume":"7","author":"S Anttila","year":"2007","unstructured":"Anttila S, Kampman O, Illi A, Rontu R, Lehtimaki T, Leinonen E . Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007; 7: 22.","journal-title":"BMC Psychiatry"},{"key":"BFmp200989_CR62","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/ajmg.b.30468","volume":"144B","author":"D Mancama","year":"2007","unstructured":"Mancama D, Mata I, Kerwin RW, Arranz MJ . Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 849\u2013853.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFmp200989_CR63","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/0269881106072341","volume":"21","author":"R Hwang","year":"2007","unstructured":"Hwang R, Shinkai T, De LV, Ni X, Potkin SG, Lieberman JA et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007; 21: 718\u2013727.","journal-title":"J Psychopharmacol"},{"key":"BFmp200989_CR64","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.1142364","volume":"316","author":"E Zeggini","year":"2007","unstructured":"Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336\u20131341.","journal-title":"Science"},{"key":"BFmp200989_CR65","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1038\/sj.onc.1202874","volume":"18","author":"X Fu","year":"1999","unstructured":"Fu X, McGrath S, Pasillas M, Nakazawa S, Kamps MP . EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1. Oncogene 1999; 18: 4920\u20134929.","journal-title":"Oncogene"},{"key":"BFmp200989_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1006\/dbio.1997.8638","volume":"188","author":"M Sefton","year":"1997","unstructured":"Sefton M, Araujo M, Nieto MA . Novel expression gradients of Eph-like receptor tyrosine kinases in the developing chick retina. Dev Biol 1997; 188: 363\u2013368.","journal-title":"Dev Biol"},{"key":"BFmp200989_CR67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00335-005-0157-1","volume":"17","author":"W Traut","year":"2006","unstructured":"Traut W, Weichenhan D, Himmelbauer H, Winking H . New members of the neurexin superfamily: multiple rodent homologues of the human CASPR5 gene. Mamm Genome 2006; 17: 723\u2013731.","journal-title":"Mamm Genome"},{"key":"BFmp200989_CR68","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.1073\/pnas.191360198","volume":"98","author":"XZ Xu","year":"2001","unstructured":"Xu XZ, Moebius F, Gill DL, Montell C . Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform. Proc Natl Acad Sci USA 2001; 98: 10692\u201310697.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200989_CR69","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.tpj.6500342","volume":"6","author":"MA Davies","year":"2006","unstructured":"Davies MA, Setola V, Strachan RT, Sheffler DJ, Salay E, Hufeisen SJ et al. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 2006; 6: 42\u201351.","journal-title":"Pharmacogenomics J"},{"key":"BFmp200989_CR70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00003088-200038050-00002","volume":"38","author":"S Caccia","year":"2000","unstructured":"Caccia S . Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000; 38: 393\u2013414.","journal-title":"Clin Pharmacokinet"},{"key":"BFmp200989_CR71","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","volume":"46","author":"MC Mauri","year":"2007","unstructured":"Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De GI, Bareggi SR . Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359\u2013388.","journal-title":"Clin Pharmacokinet"},{"key":"BFmp200989_CR72","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10519-006-9135-y","volume":"37","author":"EJCG Van den Oord","year":"2007","unstructured":"Van den Oord EJCG, McClay J, York T, Murrelle L, Robles JR . Genetics and diagnostic refinement. Behav Genet 2007; 37: 535\u2013545.","journal-title":"Behav Genet"},{"key":"BFmp200989_CR73","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/pgs.09.19","volume":"10","author":"TP York","year":"2009","unstructured":"York TP, Vargas-Irwin C, Anderson W, van den Oord EJ . The use of finite mixture models to handle drug response heterogeneity in pharmacogenetics studies. Pharmacogenomics 2009; 10: 753\u2013767.","journal-title":"Pharmacogenomics"},{"key":"BFmp200989_CR74","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1086\/324471","volume":"69","author":"HH Goring","year":"2001","unstructured":"Goring HH, Terwilliger JD, Blangero J . Large upward bias in estimation of locus-specific effects from genomewide scans. Am J Hum Genet 2001; 69: 1357\u20131369.","journal-title":"Am J Hum Genet"},{"key":"BFmp200989_CR75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/ng749","volume":"29","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG . Replication validity of genetic association studies. Nat Genet 2001; 29: 306\u2013309.","journal-title":"Nat Genet"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp200989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp200989","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp200989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T22:59:46Z","timestamp":1739314786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp200989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFmp200989"],"URL":"https:\/\/doi.org\/10.1038\/mp.2009.89","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]},"assertion":[{"value":"22 January 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eli Lilly funded the GWAS genotyping conducted at Perlegen Sciences. Dr Sullivan reports receiving research funding from Eli Lilly in connection with this project. Dr Stroup reports receiving research funding from Eli Lilly and consulting fees from Janssen Pharmaceutica, GlaxoSmithKline and Bristol-Myers Squibb. Dr Lieberman reports receiving research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica and Pfizer, and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer and Solvay.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}